SARS-CoV-2 is the third coronavirus to emerge in humans over the past two decades, and currently-available vaccines face challenges in durability and protection from new variants. There is a critical need for a new, proactive approach to research and development (R&D) for coronavirus vaccines that may confer greater protection and durability against new SARS-CoV-2 variants, as well as protection against new and emerging coronaviruses with pandemic potential.

To address these current and future pandemic threats, CIDRAP is leading an international collaborative effort to develop a coronavirus vaccines R&D roadmap (CVR). Advancing a global R&D agenda for broadly protective coronavirus vaccines is a large and complex endeavor that will require ongoing investment, communication, and coordination among researchers, governments, industry, multilateral and nongovernmental organizations, regulatory authorities, and public health policymakers. The purpose of this roadmap is to provide a framework and timeline to align coordination, leadership, and investment to achieve these ambitious goals.

The CVR will focus on identifying key goals and milestones necessary to develop vaccines that provide broad protection against coronaviruses.

CIDRAP has engaged global expert stakeholders to guide the roadmap development process, including leaders on key issues for coronavirus vaccine development, such as virology, immunology, animal models, and policy and regulatory issues. The draft roadmap was available for public review and comment from October 24 - November 18, 2022. The final roadmap will be made publicly available in early 2023.

The CVR project is funded by The Rockefeller Foundation and the Bill & Melinda Gates Foundation.